Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression

Journal of the National Cancer Institute

Volumn 92, Issue 1, 2000, Pages 69-73

  Shin, Dong M ^a   Mao, Li ^a   Papadimitrakopoulou, Vassiliki M ^a   Clayman, Gary ^a   El Naggar, Adel ^a   Shin, Hyung Ju C ^a   Lee, J Jack ^a   Lee, Jin S ^a   Gillenwater, Ann ^a   Myers, Jeffrey ^a   Lippman, Scott M ^a   Hittelman, Walter N ^a   Hong, Waun Ki ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; ISOTRETINOIN; PROTEIN P53;

ARTICLE; CANCER PREVENTION; CLINICAL TRIAL; DRUG MEGADOSE; DRUG RESPONSE; GENE EXPRESSION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; PHASE 2 CLINICAL TRIAL; PRECANCER; PRIORITY JOURNAL;

EID: 2042533909     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.1.69     Document Type: Article

References (34)

1. Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993;328:15-20.
2. Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984;53:563-8.
3. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501-5.
4. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
5. Lippman SM, Benner SE, Hong WK. Chemoprevention: strategies for the control of cancer. Cancer 1993;72:984-90.
6. Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993;11:1216-22.
7. Maxwell SA, Mukhopadhyay T. Transient stabilization of p53 in non-small cell lung carcinoma cultures arrested for growth by retinoic acid. Exp Cell Res 1994;214:67-74.
8. Kim SY, Berger DH, Storthz K, Hong WK, Li SC, Yim SO, et al. Molecular markers of retinoid response in oral squamous carcinoma [abstract]. Proc Am Assoc Cancer Res 1994;35:A3716.
9. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992;10:839-64.
10. Delaney TF, Afridi N, Taghian AG, Sanders DA, Fuleihan NS, Faller DV, et al. 13-cis-Retinoic acid with alpha-2α-interferon enhances radiation cytotoxicity in head and neck squamous cell carcinoma in vitro. Cancer Res 1996;56:2277-80.
11. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid and interferon-α act synergistically as antiangiogenic and antitumor agents against human head and neck squamous carcinoma. Cancer Res 1998;58:5551-8.
12. Lindner DJ, Borden EC, Kalvakolanu DV. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res 1997;3:931-7.
13. Killa V, Weihua X, Kalvakolanu DV. Modulation of interferon action by retinoids. Induction of murine STAT1 gene expression by retinoic acid. J Biol Chem 1997;272: 9742-8.
14. Pelicano L, Li F, Schindler C, Chelbi-Alix MK. Retinoic acid enhances the expression of interferon-induced proteins: evidence for multiple mechanisms of action. Oncogene 1997;6:2349-59.
15. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, et al. 13-cis-Retinoic acid and interferon alpha-2α: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235-41.
16. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, et al. 13-cis-Retinoic acid plus interferon-alpha-2a in locally advanced squamous cell carcinoma of the cervix. J Natl Cancer Inst 1993;85:499-500.
17. Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, et al. Interferon alpha-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995;13:1950-7.
18. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351: 453-6.
19. Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 1992;7:927-33.
20. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54:321-6.
21. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
22. Shin DM, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, et al. p53 expression: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:519-29.
23. Lippman SM, Shin DM, Lee JJ, Batsakis JG, Lotan R, Tainsky MA, et al. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 1995;55:16-9.
24. Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, et al. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surgery 1999;125:1083-9.
25. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2: 682-5.
26. Kim SK, Fan Y, Papadimitrakopoulou V, Clayman G, Hittelman WN, Hong WK, et al. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res 1996;56: 2519-21.
27. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 1989;10:1-10.
28. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53: 4477-80.
29. Mao EJ, Schwartz SM, Daling JR, Oda D, Tickman L, Beckmann AM. Human papilloma viruses and p53 mutations in normal, premalignant and malignant oral epithelia. Int J Cancer 1996;69:152-8.
30. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell 1992;71:587-97.
31. Zhan Q, Carrier F, Fornace AJ Jr. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol 1993;13:4242-50.
32. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74: 957-67.
33. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997; 278:1073-7.
34. Mao L, El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998;90:1545-51.